282 related articles for article (PubMed ID: 23371447)
1. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
Zhu H; Garcia JA
Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
[TBL] [Abstract][Full Text] [Related]
2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
3. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
4. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
5. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
6. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
9. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
11. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Gupta E; Guthrie T; Tan W
BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
[TBL] [Abstract][Full Text] [Related]
12. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
Roviello G; Pacifico C; Chiriacò G; Generali D
Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
[TBL] [Abstract][Full Text] [Related]
15. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
17. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
Eichholz A; Ferraldeschi R; Attard G; de Bono JS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):68-75. PubMed ID: 21986558
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
20. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
